Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,668 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 35,668 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001193125-26-417236 · ownership.xml · derivative · entry 2 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-10-05 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-417236 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,668 F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleCommon Stock | 432 | $6.01 | $2,596.32 |
DisclosureSEC source: 0001193125-26-349960 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,968 F1 · kind: On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · derivative · entry 16 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,000 shares Expires 2026-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · derivative · entry 15 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · derivative · entry 14 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 32,230 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · derivative · entry 13 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 32,230 shares Expires 2029-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 21,000 | $12.75 | $267,750.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 12 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 21,000 | $5.97 | $125,370.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 11 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 21,000 | $12.75 | $267,750.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 10 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 21,000 | $3.50 | $73,500.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 9 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 25,000 | $15.00 | $375,000.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 8 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 20,000 | $12.75 | $255,000.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 7 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 45,000 | $4.59 | $206,325.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 6 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 17,230 | $15.00 | $258,450.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 5 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 15,000 | $12.75 | $191,250.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 4 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,630 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 32,230 | $5.37 | $173,075.10 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 3 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,494 | $15.00 | $112,410.00 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 2 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,400 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,494 | $12.75 | $95,548.50 |
DisclosureSEC source: 0001193125-25-314739 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,894 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000950170-25-110287 · ownership.xml · derivative · entry 3 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,000 shares Expires 2025-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 21,000 | $9.25 | $194,250.00 |
DisclosureSEC source: 0000950170-25-110287 · ownership.xml · nonDerivative · entry 2 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,388 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 21,000 | $9.13 | $191,730.00 |
DisclosureSEC source: 0000950170-25-110287 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 152,400 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0000950170-25-108290 · ownership.xml · derivative · entry 2 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,400 Underlying: Ordinary Shares · 152,400 shares Expires 2030-08-11 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 11, 2025, through the two-year period following the grant date. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 25,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-108290 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,388 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2026 annual general meeting or August 11, 2026; and (ii) the earlier of the Company's 2027 annual general meeting or August 11, 2027. Read SEC document |
| August 05, 2025 Filed Aug 8, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,127 | $8.75 | $9,861.25 |
DisclosureSEC source: 0000950170-25-105352 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,988 F1 · shares: On August 5, 2025, the reporting person sold 1,127 ordinary shares solely to cover taxes associated with the vesting of restricted share units on August 5, 2025.These sales were made pursuant to a 10b5-1 Trading Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 32,230 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000950170-24-097289 · ownership.xml · derivative · entry 2 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,230 Underlying: Ordinary Shares · 32,230 shares Expires 2029-08-12 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 16,115 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097289 · ownership.xml · nonDerivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,115 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017916 · doc4.xml · derivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029094 · doc4.xml · derivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:07 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033519 · doc4.xml · derivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2022 annual general meeting or August 16, 2022. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023080 · doc4.xml · derivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on August 18, 2021 and the remainder vests quarterly thereafter until August 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.